Table 3.
Summary of ongoing clinical trials of N-acetyl cysteine and corona virus disease 2019
Nct
|
Drug or other interventions
|
Diseases
|
Location (State, Country)
|
Status (Recruiting or completed)
|
Results (Yes or not available)
|
Phase
|
NCT04455243 | N-acetyl cysteine vs placebo | COVID 19 | Riyadh, Saudi Arabia | Not yet recruiting | Pending | 3 |
NCT04374461 | N-acetyl cysteine vs peripheral blood | COVID 19 | New York, United States | Trial began May 2020 | Pending, expected May 2022 | 2 |
NCT04419025 | N-acetyl cysteine | COVID 19 SARS COV 2, SARS associated Coronavirus disease, Oxidative stress | Massachusetts, United States | Trial began September 2020 | Pending, expected May 2021 | 4 |
NCT04458298 | OP-101 (Dendrimer N-Acetylcysteine) Placebo | COVID 19 | California, United States | Trial began July 2020 | Pending, expected February 2021 | 2 |
COVID 19: Corona virus disease 2019; SARS COV 2: Severe acute respiratory syndrome coronavirus 2.